Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 2
2000 1
2001 1
2002 1
2009 1
2010 1
2012 1
2013 2
2015 1
2016 1
2018 2
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma.
Matschiner G, Fitzgerald MF, Moebius U, Hohlbaum AM, Gille H, Jensen K, Kirchfeld K, Rattenstetter B, Laforge A, Bel Aiba RS, Ciccotosto J, Nyugen H, Foster ML, Snouwaert JN, Nguyen M, Koller BH, Matis L, Anderson GP, Olwill SA. Matschiner G, et al. J Allergy Clin Immunol. 2023 Apr;151(4):966-975. doi: 10.1016/j.jaci.2022.12.815. Epub 2022 Dec 30. J Allergy Clin Immunol. 2023. PMID: 36592703 Free article.
Bivalent inhibition of human beta-tryptase.
Schaschke N, Matschiner G, Zettl F, Marquardt U, Bergner A, Bode W, Sommerhoff CP, Moroder L. Schaschke N, et al. Among authors: matschiner g. Chem Biol. 2001 Apr;8(4):313-27. doi: 10.1016/s1074-5521(01)00011-4. Chem Biol. 2001. PMID: 11325588
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Schüler J, Moebius U, Rothe C, Matis L, Olwill SA. Hinner MJ, et al. Among authors: matschiner g. Clin Cancer Res. 2019 Oct 1;25(19):5878-5889. doi: 10.1158/1078-0432.CCR-18-3654. Epub 2019 May 28. Clin Cancer Res. 2019. PMID: 31138587
Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs.
Danov O, Jiménez Delgado SM, Obernolte H, Seehase S, Dehmel S, Braubach P, Fieguth HG, Matschiner G, Fitzgerald M, Jonigk D, Knauf S, Pfennig O, Warnecke G, Wichmann J, Braun A, Sewald K. Danov O, et al. Among authors: matschiner g. PLoS One. 2018 Nov 30;13(11):e0207767. doi: 10.1371/journal.pone.0207767. eCollection 2018. PLoS One. 2018. PMID: 30500834 Free PMC article.
Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
Masuda Y, Yamaguchi S, Suzuki C, Aburatani T, Nagano Y, Miyauchi R, Suzuki E, Yamamura N, Nagatomo K, Ishihara H, Okuno K, Nara F, Matschiner G, Hashimoto R, Takahashi T, Nishizawa T. Masuda Y, et al. Among authors: matschiner g. J Pharmacol Exp Ther. 2018 May;365(2):368-378. doi: 10.1124/jpet.117.246652. Epub 2018 Feb 20. J Pharmacol Exp Ther. 2018. PMID: 29463608
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L. Olwill SA, et al. Among authors: matschiner g. Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3. Mol Cancer Ther. 2013. PMID: 24002935
16 results